Impact of the Biofield Energy Healing Based Test Formulation on Various Health Biomarkers Using Cell-Based Assays

Journal: Journal of Nutrition and Health Sciences  

Volume: 6 Issue: 2

ISSN: 2393-9060

Authors: Patric E, Trivedi MK, Branton A, Trivedi D, Nayak G, Gangwar M, and Jana S

Citation: Patric E, Trivedi MK, Branton A, Trivedi D, Nayak G, et al. (2019) Impact of the Biofield Energy Healing Based Test Formulation on Various Health Biomarkers Using Cell-Based Assays. J Nutr Health Sci 6(2): 205

  • 12 Views
  • Downloads

Abstract

Various complementary approaches have been used against multiple organ dysfunction syndrome (MODS), which is the major contributor in high mortality among the healthcare centers. The aim of the present study was to determine the impact of the Biofield Energy Treatment on test formulation and different cell line medium related with vital organs functioning. Different organ based cell lines were used in the study for testing the effects of test formulation. The test item (TI) and specific cell line media (Med) was divided into two parts; one untreated (UT-TI) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Elizabeth Patric, USA and were labeled as the Biofield Energy Treated (BT) test formulation/media. MTT assay was used for cell viability assay, and the results showed that the test item was found non-toxic. Cytoprotective action of the test formulation showed a significant maximum restoration of cell viability by 129.7% (at 1 µg/mL), 28.4% (at 63.75 µg/mL), and 44.5% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group in human cardiac fibroblasts cells (HCF) cells, while 53.4% (at 63.75 µg/mL), 14.5% (at 10 µg/mL), and 22.9% (at 25.5 µg/mL) improved cellular protection of human hepatoma cells (HepG2) cells in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. In addition, cytoprotective activity in adenocarcinoma human alveolar basal epithelial cells (A549) showed improved cell viability by 25.6% (at 25.5 µg/mL), 59.8% (at 10 µg/mL), and 26.1% (at 1 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. ALP activity in MG-63 cells was maximum increased by 84.9% at 50 µg/mL in the BT-Med + BT-TI group, while in Ishikawa cells showed maximum increased ALP activity by 308.1% at 0.1 µg/mL in the BT-Med + BT-TI group as compared to the untreated group. The maximum percent cellular protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 76.7% (at 1 µg/mL), 44.3% (at 1 µg/mL), and 102.6% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI group, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. Alanine amino transferase (ALT) in terms of percent protection of HepG2 (liver) cells (decreased of ALT activity) was reported at 63.75 µg/mL by 70.6%, 89.9%, and 76.6% in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group. Cellular protection of A549 (lungs) cells (increased of SOD activity) in terms of percentage was increased by 16.2% (at 10 µg/mL), 35.2% (at 63.75 µg/mL), and 17.7% (at 63.75 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to untreated group. Serotonin level was significantly increased by 14.6% (at 25 µg/mL), 41.2% (at 1 µg/mL), and 70.8% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UTTI, and BT-Med + BT-TI groups, respectively compared to untreated test group in human neuroblastoma cells (SH-SY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 166.8%, 266.4%, and 153.3% at 0.1 µg/mL in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. Thus, Biofield Energy Treated test formulation (The Trivedi Effect®) would be significantly useful for multiple organ health that can be used against coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.

Conclusion

MTT assay showed that the test formulation was found safe all the tested cell lines. Cytoprotective activity against t-BHP induced cell damage was tested using human cardiac fibroblasts cells (HCF), which showed restoration of cell viability by 129.7% (at 1 µg/mL), 28.4% (at 63.75 µg/mL), and 44.5% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group, while in HepG2 cells the maximum restoration of cell viability by 53.4% (at 63.75 µg/mL), 14.5% (at 10 µg/mL), and 22.9% (at 25.5 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group. Similarly, the test formulation in A549 cells showed maximum restoration of cell viability by 25.6% (at 25.5 µg/mL), 59.8% (at 10 µg/mL), and 26.1% (at 1 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. ALP activity in MG-63 cells showed significantly increased ALP activity by 81.2% (at 10 µg/mL), 80.8% (at 10 µg/mL), and 84.9% (at 50 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI group, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. Similarly, ALP activity in Ishikawa cells with maximum cellular protection at 0.1 µg/mL by 64%, 165.1%, and 308.1% in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups respectively, as compared to the untreated test group. LDH data was presented in terms of increased percentage cellular protection data, which suggested significant decreased activity, which showed maximum cellular protection by 76.7% (at 1 µg/mL), 44.3% (at 1 µg/mL), and 102.6% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI group, and BT-Med + BT-TI groups respectively, as compared to the untreated test group. ALT activity was studied and data showed maximum improved cellular protection of HepG2 cells (decreased of ALT activity) at 63.75 µg/mL by 70.6%, 89.9%, and 76.6% in the UT-Med + BT-TI, BT-Med + UT-TI group, and BT-Med + BT-TI groups respectively, as compared with the untreated test group. SOD activity was significantly increased by 16.2% (at 10 µg/mL), 35.2% (at 63.75 µg/mL), and 17.7% (at 63.75 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI group, and BT-Med + BT-TI groups respectively, as compared with the untreated test group. Serotonin level was significantly increased in SH-SY5Y cells by 14.6% (at 25 µg/mL), 41.2% (at 1 µg/mL), and 70.8% (at 10 µg/mL) in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups respectively, as compared with the untreated test group. However, VDR expression was tested in MG-63 cells, which showed increased RQ of VDR by 166.8%, 43.1%, and 43.2% in the UT-Med + BT-TI group at 0.1, 1, and 10 µg/mL respectively, while 266.4%, 174.4%, and 178.4% increased RQ of VDR at 0.1, 1, and 10 µg/mL respectively, in the BT-Med + UT-TI group, and increased RQ of VDR by 153.3%, 60.5%, and 85.6% at 0.1, 1, and 10 µg/mL respectively, in the BT-Med + BT-TI group as compared to the untreated test control group. Thus, Biofield Energy Treatment (The Trivedi Effect®) can be used for improving overall health such as significant role in cardiac disorders such as stroke, thromboembolic disease, congestive heart failure, congenital heart disease, peripheral artery disease, rheumatic heart disease, valvular heart disease, and venous thrombosis, etc. Besides, it would also protect against many hepatic disorders (cirrhosis, liver cancer, hemochromatosis, Wilson disease), lungs disorders (asthma, chronic bronchitis, emphysema, cystic fibrosis, and pneumonia), and many immune system related disorders. In addition, this novel test formulation can also be utilized for organ transplants (i.e., kidney, liver, and heart transplants), hormonal imbalance, aging, and various inflammatory and immune-related disease conditions like Asthma, Aplastic Anemia, Graves’ Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Dermatitis, Diabetes, Parkinson’s Disease, Myasthenia Gravis, Ulcerative Colitis (UC), Atherosclerosis, etc. to improve overall health and Quality of Life.